Tumor-specific crosslinking of GITR as costimulation for immunotherapy

Journal of Immunotherapy

Volumn 33, Issue 9, 2010, Pages 925-934

  Burckhart, Tanja ^a   Thiel, Markus ^a   Nishikawa, Hiroyoshi ^c   Wüest, Thomas ^a   Müller, Dafne ^d   Zippelius, Alfred ^b   Ritter, Gerd ^e   Old, Lloyd ^e   Shiku, Hiroshi ^c   Renner, Christoph ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF STUTTGART   (Germany)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

costimulation; fibroblast activation protein; glucocorticoid induced tumor necrosis factor related receptor ligand; regulatory T cell

Indexed keywords

DIMER; FIBROBLAST ACTIVATING PROTEIN ANTIBODY GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RELATED RECEPTOR LIGAND FUSION PROTEIN; FIBROBLAST ACTIVATION PROTEIN; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HYBRID PROTEIN; INTERLEUKIN 2; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG PROTEIN BINDING; EFFECTOR CELL; FIBROBLAST; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; STROMA; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; TUMOR REJECTION;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; GELATINASES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 78149284338     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181f3cc87     Document Type: Article

References (42)

1. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
2. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942-949.
3. +/regulatory T-cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543.
4. Nocentini G, Giunchi L, Ronchetti S, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T-cell receptor-induced apoptosis. Proc Natl Acad Sci U S A. 1997;94:6216-6221.
5. McHugh RS, Whitters MJ, Piccirillo CA, et al. CD4 (+) CD25 (+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002;16:311-323.
6. +T cells. J Immunol. 2004;172:7306-7314.
7. Tone M, Tone Y, Adams E, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A. 2003;100:15059-15064.
8. Ronchetti S, Zollo O, Bruscoli S, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T-lymphocyte subpopulations. Eur J Immunol. 2004;34:613-622.
9. Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25 (+) CD4 (+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.
10. +T cells. J Immunol. 2004;173:5008-5020.
11. +T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood. 2005;105:2845-2851.
12. Hu P, Arias RS, Sadun RE, et al. Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. Clin Cancer Res. 2008;14:579-588.
13. +T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 2008;68:5948-5954.
14. +effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J Immunol. 2007;179:7365-7375.
15. +regulatory T cells mediated by GITR molecules. Immunol Lett. 2008;121:97-104.
16. +regulatory T cells. J Exp Med. 2005;202:885-891.
17. Piao J, Kamimura Y, Iwai H, et al. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology. 2009;127:489-499.
18. +T-cell dependent anti-tumor immunity. Cancer Immunol Immunother. 2009;58:1057-1069.
19. Calmels B, Paul S, Futin N, et al. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther. 2005;12:198-205.
20. Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8 (+) T-cell responses and tumor immunity. Cancer Res. 2006;66:4904-4912.
21. Liu Z, Tian S, Falo LD Jr, et al. Therapeutic immunity by adoptive tumor-primed CD4 (+) T-cell transfer in combination with in vivo GITR ligation. Mol Ther. 2009;17:1274-1281.
22. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994;91:5657-5661.
23. Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005;5:10.
24. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;87:7235-7239.
25. Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroecto-dermal origin. Cancer Res. 1993;53:3327-3335.
26. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like syno-viocytes. Arthritis Res Ther. 2006;8:R171.
27. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768-1778.
28. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639-1647.
29. Brocks B, Garin-Chesa P, Behrle E, et al. Species-crossreactive scFv against the tumor stroma marker "fibroblast activation protein" selected by phage display from an immunized FAP-/- knock-out mouse. Mol Med. 2001;7:461-469.
30. Cheng JD, Dunbrack RL Jr, Valianou M, et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res. 2002;62:4767-4772.
31. Thiel M, Wolfs MJ, Bauer S, et al. Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. Immunology. 2010;129:28-40.
32. Suvas S, Kim B, Sarangi PP, et al. In vivo kinetics of GITR and GITR ligand expression and their functional significance in regulating viral immunopathology. J Virol. 2005;79:11935-11942.
33. +T cells. J Immunol. 2007;179:5916-5926.
34. Dittmer U, He H, Messer RJ, et al. Functional impairment of CD8 (+) T cells by regulatory T cells during persistent retroviral infection. Immunity. 2004;20:293-303.
35. +T-cell responses enhances antiparasitic immunity. J Immunol. 2010;184:2583-2592.
36. Ji HB, Liao G, Faubion WA, et al. Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T-cell suppression. J Immunol. 2004;172:5823-5827.
37. Bossen C, Ingold K, Tardivel A, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem. 2006;281:13964-13971.
38. Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, et al. Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. Proc Natl Acad Sci U S A. 2007;104:19452-19457.
39. Zhou Z, Song X, Berezov A, et al. Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states. Proc Natl Acad Sci U S A. 2008;105:5465-5470.
40. Chattopadhyay K, Ramagopal UA, Brenowitz M, et al. Evolution of GITRL immune function: murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci U S A. 2008;105:635-640.
41. Gurney AL, Marsters SA, Huang RM, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol. 1999;9:215-218.
42. +regulatory T cells. Int Immunol. 2010;22:259-270.